logo
Search…
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Search...
search
home
TOP News
Latest
RecommendHK StockUS StockChina StockMacroBond
Commercial
GlobalInvestment&FinancingCompany&ProductsCharacterESG
Economy&politics
Hong KongChinaAmerica
Stocks
HK StockChina StockUS Stock
Markets
HK StockUS Stock
IPO
Hong KongAmericaChina
Research
US StockHK Stock
Opinion
Recommendation
Home > Stocks > HK Stock

Zhongji Innolight (03308) spent approximately 217 million yuan to repurchase about 239,000 A-shares on September 9.

date
17:40 09/09/2026
avatar
GMT Eight
Zhongji Xuchuang (03308) announced that on September 9, 2026, it will spend approximately 217 million yuan to repurchase about 239,000 A-share shares.
Zhongji Innolight (03308) announced that on September 9, 2026, it spent approximately 217 million yuan to repurchase about 239,000 A-share shares.
Related Articles
HK Stock
YAN PALACE (01497) repurchased 30,000 shares at a cost of HKD 189,000 on September 9.
HK Stock
Semiconductor Manufacturing International Corporation (00981) issued 78,400 shares due to the vesting of restricted stock units.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): The drug marketing authorization application for Reproglycosidase Injection has been accepted by the National Medical Products Administration.
YAN PALACE (01497) repurchased 30,000 shares at a cost of HKD 189,000 on September 9.
HK Stock
Semiconductor Manufacturing International Corporation (00981) issued 78,400 shares due to the vesting of restricted stock units.
HK Stock
Jiangsu Hengrui Pharmaceuticals (01276): The drug marketing authorization application for Reproglycosidase Injection has been accepted by the National Medical Products Administration.
HK Stock
RECOMMEND
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
Hot A‑Share Stocks Clarify Physical AI, Robotics, Aerospace, and Duty‑Free Themes Amid Frenzied Trading
icon
10/06/2026
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
U.S. AI Trading Frenzy Collapses as Jobs Data Fuels Fed Hike Fears
icon
10/06/2026
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
Goldman Sachs Warns of AI‑Driven Market Heat, But Bubble Indicators Still Below Historical Extremes
icon
10/06/2026
logo
Contact US
qr
+852 - 60190728
gmteight@futurecultural.com
Customer Support
About Us
Contact Us
Frequently Asked
Privacy Policy
Terms of Use
Commercial Services
Advertising
Business Development
Copyright
Terms of Service
©️2013 - 2026 GMT EIGHT Holdings. All Rights Reserved.